MEB Medibio

Departure of Managing Director & Chief Executive Officer

Departure of Managing Director & Chief Executive Officer

SYDNEY, Australia and MINNEAPOLIS, Aug. 29, 2018 (GLOBE NEWSWIRE) -- The Board of Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), today announced that Mr. Jack Cosentino will cease as Managing Director and Chief Executive Officer of the Company. His departure is effective from August 28, 2018. Mr. Cosentino was appointed Managing Director and Chief Executive Officer on February 16, 2017.

Medibio further advises that Mr. Brian Mower has been appointed Interim CEO effective as at August 28, 2018. Mr. Mower is the Company’s Chief Financial Officer and has been part of the Medibio team since April 2017. The Board will commence a search immediately for a new CEO and Managing Director and will consider both internal and external candidates.

Medibio Board of Directors Chairman Chris Indermaur said “The Company will remain focused and steadfast on its continued mission in identifying the link between physiological measures and mental health. We are fortunate to have the experience and dedication of Brian to move the company forward in the right direction whilst we embark on our search for a new CEO.”

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices now located in Melbourne (Vic), Perth (WA) and Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on and

Further Information: 
Medibio Media Inquiries:

Josh Purdy

Public Relations Director

Medibio Limited



T: 952-314-1216		 
EN
29/08/2018

Underlying

MEBMedibio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medibio

 PRESS RELEASE
Free
MEB MEDIBIO

Medibio Signs Insurance Company AIA Australia Ltd (AIAA) For an Exclus...

Medibio Signs Insurance Company AIA Australia Ltd (AIAA) For an Exclusive Pilot Program For ilumen™ SYDNEY, Australia and MINNEAPOLIS, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company announces that it has signed an exclusive agreement with AIAA to undertake a pilot program for the latest release of its corporate health program, ilumen™. AIAA is one of Australia’s leading life insurers, offering a range of products that protect the financial health and wellbeing of more than 4 million Australians.  AIAA is ...

November 27, 2018 1 EN
 PRESS RELEASE
Free
MEB MEDIBIO

Medibio Appoints Global Healthcare & Medical Device Leader as CEO and ...

Medibio Appoints Global Healthcare & Medical Device Leader as CEO and Managing Director SYDNEY, Australia and MINNEAPOLIS, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, announces the appointment of David B. Kaysen as CEO and Managing Director. Mr. Kaysen brings more than 35 years of experience leading and managing both domestic and international emerging growth companies. He has achieved consistent and solid results with bio-pharmaceutical, medical device, and clinical software/IT companies. He is exper...

November 2, 2018 1 EN
 PRESS RELEASE
Free
MEB MEDIBIO

Medibio Market Update

Medibio Market Update SYDNEY, Australia and MINNEAPOLIS, Minn., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX: MEB)(OTCQB: MDBIF), a mental health technology company, today shares a market update to the recent quarterly update. ISO 13485 CertificationThis week the company completed the annual audit process for certification of the Company’s Quality Management System.  The audit was conducted by DQS Med, the Notified Body appointed to assess our compliance. There were no major or minor findings, providing further evidence of the stability of our quality s...

November 2, 2018 1 EN
 PRESS RELEASE
Free
MEB MEDIBIO

Medibio Limited Quarterly ASX Update and Cashflows

Medibio Limited Quarterly ASX Update and Cashflows Quarterly Update and Message from Medibio Limited SYDNEY, Australia and MINNEAPOLIS, Minn., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX: MEB)(OTCQB: MDBIF), a mental health technology company provides the following quarterly update: Key highlights from the quarter Announced clinical study results - showing an improvement of more than 20% to current diagnostic standard- Achievement of 70% accuracy, 70% sensitivity and 71% specificity results - demonstrating utility as diagnostic aide and long-term monitor...

October 30, 2018 1 EN
 PRESS RELEASE
Free
MEB MEDIBIO

Medibio Signs ilumenâ„¢ Corporate Contract with a Large Australian Em...

Medibio Signs ilumen™ Corporate Contract with a Large Australian Employer SYDNEY, Australia and MINNEAPOLIS, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX: MEB) (OTCQB: MDBIF), a mental health technology company, announces a contract for the latest release of its corporate health program, ilumen™. ilumen™ is unique to the corporate health market as it integrates unique and proprietary objective biometrics with subjective assessments. Users can access and monitor this data from their personal devices, measuring and tracking biometrics through the use of wear...

October 24, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch